The Thyroid Eye Disease Market Size is valued at USD 2.15 billion in 2023 and is predicted to reach USD 3.31 billion by the year 2031 at a 5.7% CAGR during the forecast period for 2024-2031.
Thyroid Eye Disease is an autoimmune condition that causes eye swelling, bulging, and pain, often linked to Graves' disease. Treatments include Tepezza, corticosteroids, and surgery to reduce symptoms like eye bulging and vision problems.
Improved healthcare settings, improvements in autoimmune disease treatment, and positive patient compliance percentage are factors expected to drive the growth of the global Thyroid Eye Disease market. Increasing research & development activities and rising investment are some of the other factors expected to augment the target market growth. The increasing adoption of artificial tears and lubricating eye drops to alleviate dryness and give temporary relief from discomfort globally is expected to boost the market expansion in the coming years.
However, the high cost of Thyroid Eye Disease and lack of a clear thyroid eye treatment, coupled with the COVID-19 outbreak, are factors that may limit growth of the target market during the forecast period. Furthermore, increasing R&D activities, government actions to use sustainable components for production, investments by prominent players are factors expected to create lucrative growth opportunities in terms of revenue for players operating in the global Thyroid Eye Disease market over the forecast period.
Competitive Landscape
Some Major Key Players In The Thyroid Eye Disease Market:
- Horizon Therapeutics
- Viridian Therapeutics
- Pierre Fabre/ACELYRIN
- HanAll Biopharma/Harbour BioMed/Immunovant
- Sling Therapeutics
- Other Market Players
Market Segmentation:
The Thyroid Eye Disease market is segmented on the basis of marketed treatment and pipeline treatment. Based on the marketed treatment, the market is segmented as tepezza (Teprotumumab). By pipeline treatment, the market is segmented into VRDN 001, VB 421, batoclimab, and linsitinib.
Based On Marketed Treatment, The TEPEZZA (Teprotumumab) Segment Is Accounted As A Major Contributor In The Thyroid Eye Disease Market.
The TEPEZZA (Teprotumumab) category is expected to hold a major share of the global Thyroid Eye Disease market in 2023. This is attributed to help in reducing eye bulges and double vision. Additionally, it also decreases the signs and symptoms of thyroid eye disease, including eye pain, edema, and eye disease.
VRDN-001 Segment Witnessed Growth At A Rapid Rate
The VRDN-001 segment is projected to grow at a rapid rate in the global Thyroid Eye Disease market owing to growing use in treating several fatal diseases. The VRDN-001 is an intravenous monoclonal antibody that goals the anti-insulin-like growth factor-1 receptor. The major benefit of using VRDN-001 in treating these diseases is that they are taken from a biological source.
In The Region, The North America Thyroid Eye Disease Market Holds A Significant Revenue Share.
The North America Thyroid Eye Disease market is expected to report the most increased market share in terms of revenue. This can be attributed to the strong focus on the treatment of thyroid eye disease in the region. In addition, the growing prevalence of several thyroid diseases and advancement in treatment options for Thyroid Eye Disease is also expected to increase the growth of the target market. Growing healthcare setups and rising research and development activities in the region are factors increasing the growth of the target market in the region. In addition, the region Asia Pacific is projected to grow rapidly in the global Thyroid Eye Disease market due to growing concerns about thyroid eye disease, increasing healthcare expenditure, government initiatives, and increasing funding in various industries.
Recent Developments:
- In March 2024, ACELYRIN, INC. announced positive proof-of-concept results from a Phase ½ trial of lonigutamab in thyroid eye condition that is now underway. Lonigutamab is a subcutaneous (SC) humanized IgG1 monoclonal antibody that aims the insulin-like growth factor-1 receptor (IGF-1R), a known mechanism of action for thyroid eye disease treatment.
Thyroid Eye Disease Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.15 Bn |
|
Revenue Forecast In 2031 |
USD 3.31 Bn |
|
Growth Rate CAGR |
CAGR of 5.7% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Marketed Products, Pipeline treatment |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Horizon Therapeutics, Viridian Therapeutics, Pierre Fabre/ACELYRIN, HanAll Biopharma/Harbour BioMed/Immunovant, and Sling Therapeutics. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
